DENVER, Colo., Oct 30, 2025 (247marketnews.com)- Intensity Therapeutics (NASDAQ:INTS) announced a major milestone this week with the publication of its Phase 1/2 clinical results for INT230-6, an investigational intratumoral cancer therapy, in eBioMedicine, part of The Lancet Discovery Science family of journals. The open-access paper details safety, efficacy, and immune activation data in patients with metastatic or treatment-resistant cancers.
Led by Dr. Jacob S. Thomas and senior author Dr. Anthony El-Khoueiry of the University of Southern California (USC), the study evaluated INT230-6 across more than 20 cancer types. Among 64 heavily pretreated patients, the therapy achieved a 75% disease control rate and a median overall survival (mOS) of 11.9 months, a notable improvement compared with historical outcomes of 4 to 7 months in similar studies. In patients with metastatic sarcoma treated with INT230-6 alone, mOS reached 21.3 months.
Importantly, patients receiving doses that covered more than 40% of their total tumor burden showed superior outcomes, an 83% disease control rate and mOS of 18.7 months, compared with 3.1 months in those receiving smaller doses. About 20% of patients in this higher-dose group also experienced regression in uninjected tumors, a rare abscopal effect suggesting systemic immune activation.
Dr. Thomas noted that INT230-6 demonstrated favorable safety and promising efficacy, adding that most of the drug remained localized within injected tumors, over 95% of active agents, with minimal systemic exposure. No grade 4 or 5 treatment-related adverse events were reported. Dr. El-Khoueiry emphasized that the observed abscopal effects and increased infiltration of activated CD4+ and CD8+ T cells “highlight this intratumoral therapy’s potential to drive both a local and systemic anti-cancer activity.”
Company founder and CEO Lewis H. Bender called the publication “the culmination of over a decade of research,” underscoring that INT230-6 may represent one of the first locally administered monotherapies to show a potential survival benefit in metastatic disease. He added that Intensity Therapeutics has already launched randomized controlled trials, including a Phase 3 sarcoma study (NCT06263231).
The company will host a webinar with Drs. Thomas and El-Khoueiry on Friday, October 31, 2025, at 9:00 a.m. ET to discuss the findings. Interested participants can join at https://event.choruscall.com/mediaframe/webcast.html?webcastid=6uG6ARFf
The post Intensity Therapeutics’ Novel Cancer Therapy Shows Promise in Lancet Discovery Science Journal appeared first on 24/7 MarketNews.
